Skip to main content

STERIS Value Stock - Dividend - Research Selection

Steris

ISIN: IE00BFY8C754 , WKN: A2PGLV

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services. This segment offers its products and services to acute care hospitals, ambulatory surgery centers, and GI clinics. The Healthcare Specialty Services segment provides solutions and managed services, such as instrument and endoscope repair and maintenance solutions; custom process improvement consulting services; and outsourced instrument sterile processing services to acute care hospitals and other healthcare settings. The Life Sciences segment offers formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The company was founded in 1985 and is based in Dublin, Ireland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


CVRx (CVRX) Moves 11.6% Higher: Will This Strength Last?

2026-06-29
CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

STERIS (STE): Buy, Sell, or Hold Post Q1 Earnings?

2026-06-19
STERIS’s stock price has taken a beating over the past six months, shedding 20.4% of its value and falling to $202.39 per share. This might have investors contemplating their next move.

Dividend Champion, Contender, And Challenger Highlights: Week Of June 21

2026-06-18
Track weekly dividend updates for Champions, Contenders & Challengers: dividend changes, upcoming ex-dividend dates, and pay dates.

Is STERIS Stock Underperforming the Dow?

2026-06-15
While STERIS has underperformed relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Steris (STE) Stock After Q4 Miss And 2027 Outlook What The Valuation Signals Now

2026-06-12
STERIS (STE) is back in focus after reporting fourth quarter fiscal 2026 results, with adjusted earnings per share of US$2.83 missing consensus by 0.9% and revenue growth of 7.3% coming in slightly under estimates. See our latest analysis for STERIS. At a share price of US$207.22, STERIS has seen its 1-day, 7-day, 30-day and 90-day share price returns all move lower, and the year to date share price return is down 17.1%, while the 1-year total shareholder return is down 13.6%. This is despite...

[Latest] Global Gastrointestinal Endoscopy Devices Market Size/Share Worth USD 19.6 Billion by 2035 at a 5.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)

2026-06-10
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Gastrointestinal Endoscopy Devices Market size & share revenue was valued at approximately USD 11.6 Billion in 2025 and is expected to reach USD 12.2 Billion in 2026 and is expected to reach around USD 19.6 Billion by 2035, at a CAGR of 5.4% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are HOYA Corporatio

Why Is Steris (STE) Up 1% Since Last Earnings Report?

2026-06-10
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Are Options Traders Betting on a Big Move in STERIS Stock?

2026-06-09
Investors need to pay close attention to STE stock based on the movements in the options market lately.

Steris: Stable, Steady And Appealing

2026-06-09
Steris delivered nearly 9% revenue growth to $5.94B, with all segments contributing and organic growth at 7%. Learn more about STE stock here.

3 Cash-Producing Stocks We Think Twice About

2026-06-08
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.